Apoyando a los profesionales de la oncología a través de la educación

El contenido de este sitio está destinado solo a profesionales de la salud

Regístrese gratis y obtenga acceso ilimitado a nuestra extensa biblioteca de elearning

Gane puntos CME y realice un seguimiento de su actividad de aprendizaje con cientos de horas de educación médica continua.

Registrate gratis

Enhancing First-Line Treatment Strategies in Urothelial Carcinoma

The treatment landscape for UC, including muscle-invasive bladder cancer (MIBC), is rapidly advancing with new combination regimens, updated guidelines (e.g., ESMO), and a focus on multidisciplinary, personalised care. Immunotherapy-based combinations are now key in first-line treatment for advanced UC, aiming to improve survival and quality of life.

For MIBC, perioperative systemic therapies (neoadjuvant/adjuvant) are reshaping care by reducing recurrence and enhancing outcomes. Success depends on coordinated care among urologists, oncologists, and allied health professionals.

Managing adverse events (AEs) is crucial. Early recognition and proactive patient education help maintain treatment adherence and improve satisfaction.

This educational module supports best-practice adoption and informed, holistic UC care.

Published November 2025.

Enhancing First-Line Treatment Strategies in Urothelial Carcinoma

Modulo

English

0 CME Points

Guardar Ver curso

Completo Completo

Público destinatarios

Healthcare professionals who aim to personalise treatment across the urothelial carcinoma spectrum while improving patient education, communication, and adherence to optimise treatment success.

Objetivos educativos

Provide healthcare professionals with an updated understanding of emerging first-line treatment options, including combination regimens and their sequencing, to optimise patient outcomes.

Expected Practice Improvements:

Improved ability to integrate combination regimens with complementary mechanisms of action into personalised treatment plans.
Application of evidence from recent clinical trials in selecting optimal first-line therapies for locally advanced or metastatic urothelial carcinoma.

Enhancing First-Line Treatment Strategies in Urothelial Carcinoma

Público destinatarios

Objetivos educativos

Más sobre ecancer